3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
6
Withdrawn
4
Terminated
3
Active not recruiting
2
Unknown
1
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Endocrine
1
Conditions
Breast Neoplasms
1328
Neoplasms
998
Carcinoma, Non-Small-Cell Lung
865
Prostatic Neoplasms
730
Colorectal Neoplasms
671
Lung Neoplasms
553
Leukemia, Myeloid, Acute
475
Neoplasm Metastasis
427
Pancreatic Neoplasms
426
Carcinoma, Hepatocellular
407
Ovarian Neoplasms
393
Multiple Myeloma
393
Stomach Neoplasms
383
Recurrence
369
Squamous Cell Carcinoma of Head and Neck
327
Melanoma
295
Uterine Cervical Neoplasms
288
Brain Neoplasms
288
Triple Negative Breast Neoplasms
273
Glioblastoma
263
Head and Neck Neoplasms
260
Precursor Cell Lymphoblastic Leukemia-Lymphoma
256
Endometrial Neoplasms
238
Lymphoma
230
Esophageal Neoplasms
226
Rectal Neoplasms
224
Sarcoma
213
Carcinoma, Renal Cell
205
Colonic Neoplasms
196
Lymphoma, Large B-Cell, Diffuse
194
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Interventional
×
Serotonin Syndrome
×
Clear all
NCT07087054
2026-04-30
CAREFNDR
Crinetics Pharmaceuticals Inc.
Phase 3
Recruiting
141 enrolled